Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis

被引:42
作者
Blok, Joost M. [1 ,2 ]
Pluim, Ilse [1 ]
Daugaard, Gedske [3 ]
Wagner, Thomas [3 ]
Jozwiak, Katarzyna [4 ,5 ]
Wilthagen, Erica A. [6 ]
Looijenga, Leendert H. J. [7 ]
Meijer, Richard P. [1 ]
Bosch, J. L. H. Ruud [1 ]
Horenblas, Simon [2 ]
机构
[1] Univ Med Ctr Utrecht, Dept Oncol Urol, Internal Post Box C-04-236,Postbox 85500, NL-3508 GA Utrecht, Netherlands
[2] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[3] Copenhagen Univ Hosp, Dept Oncol, Copenhagen, Denmark
[4] Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands
[5] Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany
[6] Netherlands Canc Inst, Sci Informat Serv, Amsterdam, Netherlands
[7] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
关键词
testicular germ cell tumour; nonseminomatous germ cell tumour; prognostic factors; pathology; systematic review; meta-analysis; LYMPH-NODE DISSECTION; TESTICULAR-TUMORS; FOLLOW-UP; SURVEILLANCE PROTOCOL; PATHOLOGICAL STAGE; PROGNOSTIC-FACTORS; VASCULAR INVASION; IDENTIFY PATIENTS; TESTIS; CANCER;
D O I
10.1111/bju.14967
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To systematically review the literature on the prognostic value of lymphovascular invasion (LVI) and embryonal carcinoma (EC) for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour (CS I NSGCT). Materials and methods The PubMed, Embase (OVID) and SCOPUS databases were searched up to March 2019. Studies reporting on the association between LVI and/or EC and occult metastatic disease were considered for inclusion. The quality and risk of bias were evaluated by the Quality in Prognosis Studies tool. Results We screened 5287 abstracts and 207 full-text articles. We included 35 studies in the narrative synthesis and 24 studies in a meta-analysis. LVI showed the strongest effect. Pooled rates of occult metastasis were 47.5% and 16.9% for LVI-positive and LVI-negative patients, respectively (odds ratio [OR] 4.33, 95% confidence interval [CI] 3.55-5.30; P < 0.001). Pooled rates of occult metastasis were 33.2% for EC presence and 16.2% for EC absence (OR 2.49, 95% CI 1.64-3.77; P < 0.001). Pooled rates of occult metastasis were 40.0% for EC >50% and 20.0% for EC <50% (OR 2.62, 95% CI 1.93-3.56; P < 0.001). Conclusions LVI is the strongest risk factor for relapse. The prognostic value of EC is high, but there is no common agreement on how to define this risk factor. Both EC presence and EC >50% have similar ORs for occult metastasis. This shows that the assessment of EC presence is sufficient for the classification of EC.
引用
收藏
页码:355 / 368
页数:14
相关论文
共 55 条
[1]  
ALBERS P, 1995, CANCER, V75, P844, DOI 10.1002/1097-0142(19950201)75:3<844::AID-CNCR2820750316>3.0.CO
[2]  
2-C
[3]  
Albers P, 1997, CANCER, V79, P1710
[4]   Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial [J].
Albers, P ;
Siener, R ;
Kliesch, S ;
Weissbach, L ;
Krege, S ;
Sparwasser, C ;
Schulze, H ;
Heidenreich, A ;
de Riese, W ;
Loy, V ;
Bierhoff, E ;
Wittekind, C ;
Fimmers, R ;
Hartmann, M .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1505-1512
[5]   Guidelines on Testicular Cancer: 2015 Update [J].
Albers, Peter ;
Albrecht, Walter ;
Algaba, Ferran ;
Bokemeyer, Carsten ;
Cohn-Cedermark, Gabriella ;
Fizazi, Karim ;
Horwich, Alan ;
Laguna, Maria Pilar ;
Nicolai, Nicola ;
Oldenburg, Jan .
EUROPEAN UROLOGY, 2015, 68 (06) :1054-1068
[6]   Stage I non-seminomatous germ-cell tumours of the testis:: identification of a subgroup of patients with a very low risk of relapse [J].
Alexandre, J ;
Fizazi, K ;
Mahé, C ;
Culine, S ;
Droz, JP ;
Théodore, C ;
Terrier-Lacombe, MJ .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) :576-582
[7]   A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours [J].
Atsü, N ;
Eskiçorapçi, S ;
Üner, A ;
Ekici, S ;
Güngen, Y ;
Erkan, I ;
Uygur, MC ;
Özen, H .
BJU INTERNATIONAL, 2003, 92 (01) :32-35
[8]   Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors [J].
Beck, Stephen D. W. ;
Foster, Richard S. ;
Bihrle, Richard ;
Donohue, John P. .
UROLOGY, 2007, 69 (03) :557-559
[9]   Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand [J].
Colls, BM ;
Harvey, VJ ;
Skelton, L ;
Frampton, CMA ;
Thompson, PI ;
Bennett, M ;
Perez, DJ ;
Dady, PJ ;
Forgeson, GV ;
Kennedy, ICS .
BJU INTERNATIONAL, 1999, 83 (01) :76-82
[10]   Surveillance in stage I testicular cancer [J].
Daugaard, G ;
Petersen, PM ;
Rorth, M .
APMIS, 2003, 111 (01) :76-85